Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine therapy: A practice standard for Canadian nurses
Azacitidine (5-azacytidine, VIDAZA®) is a disease-modifying agent that improves survival, reduces transfusion dependence, and reduces progression to acute myeloid leukemia in patients with higher risk myelodysplastic syndromes. Azacitidine injection is associated with characteristic adverse events (...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pappin Communications
2012-10-01
|
| Series: | Canadian Oncology Nursing Journal |
| Online Access: | http://www.canadianoncologynursingjournal.com/index.php/conj/article/view/112/120 |